 - DSMB Review After Completion of the First Dose Cohort Affirmed No Safety or Tolerability Concerns with CRV431 in NASH Patients - - DSMB Recommended the AMBITION Study Continue with Final Dosing Cohort - - Final Cohort Expected to be Completed in Early 2021 - EDISON, NJ ACCESSWIRE December 29, 2020 Hepion Pharmaceuticals, Inc. NASDAQ:HEPA, Hepion, a clinical stage biopharmaceutical company focused on Artificial Intelligence AI-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis NASH and liver disease, today announced that an independent Data Safety Monitoring Board DSMB has approved the continuation of the Companys Phase 2a AMBITION clinical trial. Two interim analyses were performed by a DSMB to evaluate the safety and tolerability of the 75 mg CRV431 dose cohort in NASH patients. 